Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Chief Medical Officer | February 06, 2026 | February 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date February 06, 2026 · Filed February 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 183,914 |
Reported balance
After 2026-02-06 transaction · row 1
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 45,000 · Balance 183,914 F1: Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2036-02-06 | Direct | 210,000 |
Reported balance
After 2026-02-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-06 · Grant · Acquired 210,000 · Balance 210,000 F2: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
F2: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 10, 2026 16:33 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001104659-26-012679 · tm265871-5_4seq1.xml · derivative · entry 2 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2036-02-06 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 16:33 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-012679 · tm265871-5_4seq1.xml · nonDerivative · entry 1 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,914 F1 · shares: Consists of shares of common stock issuable under an aggregate of 45,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 14:09 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 19,000 | $3.73 | $70,870.00 |
DisclosureSEC source: 0001104659-25-080825 · tm2524007-1_4seq1.xml · nonDerivative · entry 1 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,914 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.69 to $3.79, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 16:10 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 10,086 | $3.43 | $34,594.98 |
DisclosureSEC source: 0001104659-25-032208 · tm2511532-2_4seq1.xml · nonDerivative · entry 1 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,914 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.51, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 16:16 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 126,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001104659-25-016512 · tm257355-2_4seq1.xml · derivative · entry 2 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2035-02-21 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 16:16 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 63,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-016512 · tm257355-2_4seq1.xml · nonDerivative · entry 1 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,000 F1 · shares: Consists of shares of common stock issuable under an aggregate of 63,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:17 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 105,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-043111 · tm2410775-3_4seq1.xml · nonDerivative · entry 1 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). F2 · shares: Consists of shares of common stock underlying a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is April 1, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting upon the one-year anniversary of such vesting commencement date and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued service as an employee. Read SEC document |
| March 25, 2024 Filed Mar 26, 2024 17:27 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 210,000 | $0.00 Strike: $9.26 | $0.00 |
DisclosureSEC source: 0001104659-24-039117 · tm249758-2_4seq1.xml · derivative · entry 1 Ferguson Toby · CIK 0002015616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2034-03-25 F1 · shares: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). F2 · derivative.exercise_date: The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.